Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Withdraw Califf FDA Nomination, Sanders Demands

This article was originally published in Scrip

Executive Summary

Citing close ties to the biopharmaceutical industry and a lack of commitment to lowering drug prices, Sen. Bernie Sanders (I-VT) on Jan. 26 demanded President Barack Obama withdraw his nomination of Robert Califf to lead the FDA.

You may also be interested in...



Republicans Turn Their Backs On Califf

A visual comparison of Robert Califf’s US FDA Commissioner confirmation votes in 2016 and 2022.

Califf Maintains Desire To Stay At US FDA, But Will Either Presidential Candidate Keep Him?

FDA Commissioner says every day at the agency is fun, but the decision to remain will be made by the next president.

Califf Maintains Desire To Stay At FDA, But Would Either Presidential Candidate Keep Him?

FDA Commissioner says every day at FDA is fun, but decision to remain will be made by the next president.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC064313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel